Summer greetings from Nordic Life Science!

Cereno Scientific has signed an agreement with medical technology company Fluidda on Respiratory Imaging solutions, with the aim to visualize signs of reverse remodeling of lead drug candidate CS1 in Pulmonary Arterial Hypertension (PAH) in a clinical setting.

Evaxion Biotech has entered into an option and license agreement with MSD for two preclinical vaccine candidates.

Ribocure Pharmaceuticals and Suzhou Ribo Life Science have entered a partnership with Pheiron to leverage its AI platform in Ribo’s discovery and development of RNA-based therapeutics.

We are happy to announce that we will be launching our updated and improved website this week, 16-22 September!

The 11th edition of NLSDays is being held in Malmö on September 18-19. Program Director, Marjo Puumalainen, gives us an inside look into the upcoming conference.

In the report Nordic added value in inter-ministerial Nordic co-operation, funded through NordForsk by the Nordic Council of Ministers, the researchers present six recommendations to optimize the use of the concept of ‘Nordic added value’ across Nordic institutions.

The Theranostics Trial Center (TTC) at Karolinska University Hospital has been awarded financing from Vinnova to run a new project in precision medicine. By combining image-guided diagnostics and therapy with radioactively labeled target-seeking drugs, the project aims to revolutionize cancer treatment in Sweden. “This grant is a big step for our research and a clear […]